Due to a lack of coding in the dataset, we were unable to report more nuanced and specific metrics such as duration of diabetes, total daily dose of insulin, percentage time in range and reason for starting adjunctive therapy, all of which are clinically relevant
Consulting Your Provider If you miss two or more doses, do not resume your medication without speaking to a professional
As semaglutide and tirzepatide seek to expand their approved indications, e.g., potentially adding heart failure, chronic kidney disease or MASH, following several successful phase 3 trial readouts in 2023 and 2024, more pathways open up to Medicare reimbursement of AOMs within existing rules
Most people taking GLP-1 analogues also lose weight which can be beneficial for a lot of people with type 2 diabetes
What does that concentration mean in practice